<DOC>
	<DOCNO>NCT01038856</DOCNO>
	<brief_summary>The primary objective study determine overall response rate erlotinib patient polycythemia vera ( PV ) . Response rate assess improvement complete blood count , ultrasound spleen , JAK2 molecular status . It purpose study explore possible molecular target drive mechanism PV .</brief_summary>
	<brief_title>Trial Erlotinib Patients With JAK-2 V617F Positive Polycythemia Vera</brief_title>
	<detailed_description>This phase II open-label study . Patients screen MPN diagnose patient Polycythemia vera proven JAK2V617F mutation give option enroll . Consenting patient take erlotinib daily 16 week . Blood work pharmacokinetics draw serum level monitoring . Doses administered accord side effect hold . First assessment day 15 wth subsequent assessment 28 day interval . Non-responders take study manage accord standard care . Patients respond continue take therapy total 12 month . Observation total 12 month finish treatment . In addition clinical aspect study , correlative study molecular response check correlation clinical response .</detailed_description>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>WHO 2008 diagnosis Polycythemia Vera Hemoglobin &gt; 18.5 g/dl men ( 16.5 g/dl woman ) presence JAK2V617F mutation either bone marrow trilineage myeloproliferation subnormal serum erythropoietin level Patients may active treatment ( phlebotomy , aspirin ) ECOG performance status 0,1,2 , 3 Adequate hepatic function , adequate renal function Patient active malignancy Patients clinically significant cardiac disease within 1 year Opthalmologic gastrointestinal abnormality Concurrent cytoreductive therapy allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>